FDA Approves Bristol Myers’ Opdualag for Unresectable or Metastatic Melanoma
American multinational pharmaceutical company Bristol Myers Squibb has announced that OpdualagTM , a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as one intravenous infusion,
Read more